ImmunityBio (IBRX) Return on Capital Employed (2015 - 2026)
ImmunityBio (IBRX) posted quarterly Return on Capital Employed of 51.63% for Q1 2026, up 5493.0% year-over-year from 0.92% in Q1 2025, and up 9.53% quarter-over-quarter from 57.06% in Q4 2025.
ImmunityBio (IBRX) Return on Capital Employed (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Return on Capital Employed for 12 consecutive years, with 51.63% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 5493.0% year-over-year to 51.63%; the TTM figure through Mar 2026 stood at 51.63% (up 5493.0% YoY), while the FY2025 annual figure was 67.26%, up 2128.0% from the prior year.
- Return on Capital Employed improved to 51.63% in Q1 2026 per IBRX's latest filing, from 57.06% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1489.88% in Q2 2022 and bottomed at 704.86% in Q1 2022.
- Historically, Return on Capital Employed has averaged 11.95% across 5 years, with a median of 88.32% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 166516 bps — and 2023, when it sank 136413 bps.
- ImmunityBio's Return on Capital Employed stood at 245.3% in 2022, then sank by 136 bps to 88.32% in 2023, then retreated by 22 bps to 107.96% in 2024, then surged by 47 bps to 57.06% in 2025, then increased by 10 bps to 51.63% in 2026.
- Business Quant data shows IBRX's Return on Capital Employed at 51.63% in Q1 2026, 57.06% in Q4 2025, and 64.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -44.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.90% |
| Mar 31, 2026 | -51.63% |
| Dec 31, 2025 | -57.06% |
| Sep 30, 2025 | -64.64% |
| Jun 30, 2025 | -94.41% |
| Mar 31, 2025 | -106.55% |
| Dec 31, 2024 | -107.96% |
| Sep 30, 2024 | -104.86% |
| Jun 30, 2024 | -99.91% |
| Mar 31, 2024 | -86.73% |
| Dec 31, 2023 | -88.32% |
| Sep 30, 2023 | -133.25% |
| Jun 30, 2023 | 125.75% |
| Mar 31, 2023 | 173.01% |
| Dec 31, 2022 | 245.30% |
| Sep 30, 2022 | -130.69% |
| Jun 30, 2022 | 1,489.88% |
| Mar 31, 2022 | -704.86% |
| Dec 31, 2021 | 1,208.51% |
| Sep 30, 2021 | -170.89% |